Trastuzumab Deruxtecan for Breast Cancer NEJM

Trastuzumab Deruxtecan for Breast Cancer NEJM trastuzumab trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional trastuzumab Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2

trastuzumab A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in

trastuzumab Trastuzumab exposure for a relatively short period does not seem to substantially affect the pregnancy outcome In contrast, a more prolonged Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease